Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS patients may soon get a shot instead of an IV drip

NCT ID NCT07211633

Ongoing Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety and disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ublituximab
What this could lead to
If successful, this could offer a more convenient injection option for people with multiple sclerosis, potentially replacing the need for IV infusions.
What could go wrong
This is a non-inferiority study, meaning it only aims to show the injection works as well as the IV, not better. The trial is still ongoing, and results may not confirm equivalence or could reveal safety differences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • TG Therapeutics Investigational Trial Site

    Banja Luka, 78000, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Bihać, 77000, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Mostar, 71000, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Saravejo, 71000, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Tulza, 75000, Bosnia and Herzegovina

  • TG Therapeutics Investigational Trial Site

    Pleven, 5800, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Plovdiv, 4000, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Sofia, 1000, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Sofia, 1113, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Veliko Tarnovo, 5000, Bulgaria

  • TG Therapeutics Investigational Trial Site

    Varaždin, 42000, Croatia

  • TG Therapeutics Investigational Trial Site

    Zagreb, 10000, Croatia

  • TG Therapeutics Investigational Trial Site

    Brno, 65691, Czechia

  • TG Therapeutics Investigational Trial Site

    Hradec Králové, 50005, Czechia

  • TG Therapeutics Investigational Trial Site

    Jihlava, 58601, Czechia

  • TG Therapeutics Investigational Trial Site

    Ostrava, 70300, Czechia

  • TG Therapeutics Investigational Trial Site

    Pardubice, 53002, Czechia

  • TG Therapeutics Investigational Trial Site

    Zlín, 76275, Czechia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0112, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0114, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0159, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0172, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0178, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0179, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 0180, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, 3700, Georgia

  • TG Therapeutics Investigational Trial Site

    Budapest, H-1033, Hungary

  • TG Therapeutics Investigational Trial Site

    Budapest, H-1044, Hungary

  • TG Therapeutics Investigational Trial Site

    Budapest, H-1145, Hungary

  • TG Therapeutics Investigational Trial Site

    Kaposvár, H-7400, Hungary

  • TG Therapeutics Investigational Trial Site

    Kistarsca, H-2143, Hungary

  • TG Therapeutics Investigational Trial Site

    Pécs, H-7623, Hungary

  • TG Therapeutics Investigational Trial Site

    Shtip, 7240, North Macedonia

  • TG Therapeutics Investigational Trial Site

    Skopje, 1000, North Macedonia

  • TG Therapeutics Investigational Trial Site

    Kragujevac, 34 000, Serbia

  • TG Therapeutics Investigational Trial Site

    Niš, 18000, Serbia

  • TG Therapeutics Investigational Trial Site

    Cherkasy, 14029, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, 76000, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, 76018, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ivano-Frankivsk, 76493, Ukraine

  • TG Therapeutics Investigational Trial Site

    Kyiv, 03037, Ukraine

  • TG Therapeutics Investigational Trial Site

    Kyiv, 03115, Ukraine

  • TG Therapeutics Investigational Trial Site

    Lviv, 79000, Ukraine

  • TG Therapeutics Investigational Trial Site

    Lviv, 79010, Ukraine

  • TG Therapeutics Investigational Trial Site

    Lviv, 79029, Ukraine

  • TG Therapeutics Investigational Trial Site

    Ternopil, 46027, Ukraine

  • TG Therapeutics Investigational Trial Site

    Vinnytsia, 21002, Ukraine

  • TG Therapeutics Investigational Trial Site

    Vinnytsia, 21009, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.